Cambridge Healthtech Institute’s Inaugural
Novel Peptide Drug Discovery
Discovery, Engineering, and Design
19 November 2026
Peptide drug discovery has experienced unprecedented growth and scientific momentum with this class of compounds making headlines daily, and the industry has come to appreciate the role that peptide therapeutics can play in addressing unmet medical needs. The inaugural Novel Peptide Drug Discovery conference at the PEGS Europe Summit on 19 November covers discovery, engineering, and design in this exciting area and will feature half-life extended peptides, GLP-1 agonists, and applications beyond obesity and diabetes to cardiovascular and CNS. Come learn how engineering strides are being made to allow peptides to compete and combine with established modalities.
Coverage will include, but is not limited to:
- Designing novel peptides with extended half-life and drug-like properties
- Targeting indications beyond diabetes, obesity, and metabolic diseases to cardiovascular and Alzheimer’s disease
- Addressing cell surface targets and previously undruggable pathways
- Generating novel cyclic and macrocyclic peptide libraries
- Improving computationally guided design of peptides and structure prediction
- Exploring programmable peptides and peptide-drug conjugates
- Examining novel oral-delivery strategies
The deadline for priority consideration is 26 March 2026.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
Opportunities for Participation: